JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises manufacturing and selling of pharmaceutical products. It is engaged in domestic as well as international business. The Company's main product categories include Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet, and capsules (General) and Oral Rehydration Solutions (ORS). Its beta-lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection, Cefazoline Sodium Injection, meropenem injection, amoxicillin injection, cefTAZidime injection, flucloxacillin injection, among others. Its beta-lactam tablets and capsule products include Cefadroxil Tablets, Cefadroxil Capsules, among others. Its general tablet and capsule products include Azithromycin Tablets, Iburofen Tablets, Ciprofloxacin Tablets, Ofloxacin Tablets, Paracetamol Tablets, among others. These products are offered in different milligrams (mg).
JFL LIFE SCIENCES LIMITED Financial Highlights
- Revenue: JFL LIFE SCIENCES LIMITED reported revenue of ₹131.45 crore in FY26 vs ₹82.05 crore in FY25. It showed an increase of 60.21% on a yearly basis.
- Operating Profit: JFL LIFE SCIENCES LIMITED reported an operating profit of ₹8.60 crore in FY26 vs ₹6.14 crore in FY25. It showed an increase of 40.07% on a year-on-year basis.
- Net Profit: JFL LIFE SCIENCES LIMITED reported a net profit of ₹6.40 crore in FY26 vs ₹4.16 crore in FY25. It showed an increase of 53.85% on a yearly basis.
JFL LIFE SCIENCES LIMITED Quarterly Result Highlights
- JFL LIFE SCIENCES LIMITED reported revenue of ₹63.09 crore in Mar 2026, compared with ₹26.85 crore in Dec 2025, representing an increase of 134.97% on a quarter-on-quarter (QoQ) basis.
- JFL LIFE SCIENCES LIMITED reported an operating profit of ₹2.25 crore in Mar 2026, compared with ₹2.71 crore in Dec 2025, representing a decrease of 16.97% on a quarter-on-quarter (QoQ) basis.
- JFL LIFE SCIENCES LIMITED reported a profit of ₹1.66 crore in Mar 2026, compared with ₹2.02 crore in Dec 2025, reflecting a decrease of 17.82% on a QoQ basis.
- The earnings per share (EPS) of JFL LIFE SCIENCES LIMITED stood at ₹1.26 during Mar 2026.